Navigation Links
Karius and Duke Demonstrate That the Karius Test Accurately Detects and Quantifies Microbial Cell-free DNA in Patients With Infective Endocarditis
Date:10/5/2018

Karius, a life sciences company transforming infectious disease diagnostics with genomics, along with Duke University, announced today at IDWeek™ 2018 the positive results of a study demonstrating that the Karius® Test, a non-invasive blood test that detects pathogen DNA in plasma, accurately identified causative pathogens in patients with infective endocarditis even when blood cultures were negative due to pre-treatment with antibiotics.

“The diagnosis of infective endocarditis (IE) can be difficult, especially if it is caused by organisms that are hard to grow, or if the patient has recently received antibiotic therapy. The Karius diagnostic platform offers an exciting approach to identifying the cause of endocarditis in patients with this life-threatening condition,” said Dr. Vance Fowler, professor in the Departments of Medicine and Molecular Genetics & Microbiology at Duke University Medical Center and a lead author of the study.

“The Duke Infective Endocarditis study demonstrates how the Karius Test can accurately identify the pathogen causing infective endocarditis even when the patient has been pre-treated with antibiotics,” said Dr. David K. Hong, Vice President of Medical Affairs and Clinical Development at Karius. “The test’s ability to detect and quantify over a thousand pathogens gives clinicians the unique ability to measure pathogen signal in patient plasma over time. This study shows great promise that microbial cell-free DNA as reported by the Karius Test can be a biomarker to aid in the diagnosis and monitoring of IE.”

Findings
Duke University researchers enrolled 30 hospitalized adult patients in a prospective study who were classified using the Duke Criteria for acute infective endocarditis. Blood samples were sent to the Karius laboratory, which uses next-generation sequencing to detect microbial cell-free DNA in patient plasma from over 1,000 pathogens including bacteria, DNA viruses, fungi, molds and eukaryotes.

The complete study results will be presented as an oral abstract today, Thursday, October 4: Direct Detection and Quantification of Bacterial Cell-free DNA in Patients with Infective Endocarditis (IE) Using the Karius Plasma Next Generation Sequencing (NGS) Test.

Study Overview:
The Karius Test was performed on residual plasma samples collected within 24 hours of evaluation and whole blood samples collected within 48-72 hours of enrollment as well as on samples collected every 2-3 days for up to 7 time points until discharge. Of the 29 patients eligible for analysis, 24 patients enrolled in the study were evaluated to have definite infective endocarditis. Out of these, 21 patients had culture-positive disease. The Karius Test identified the same organism as cultures in 20 patients (95.2% sensitivity) and additionally identified Enterococcus faecalis in 1 out of the 3 culture-negative patients. Pathogen cell-free DNA signal decreased on antibiotic treatment with rapid declines after surgical procedures to remove the source of infection. The test identified pathogens causing the endocarditis episode in patients pre-treated with antibiotics up to 30 days prior to initial sample collection.

In addition to Dr. Vance Fowler, Duke study authors include Pratik Shah MS, Felicia Ruffin MSN RN, Laura Winn, and Caitlin Drennan. Karius authors are Desiree Hollemon MSN, MPH, Hon Seng, Galit Meshulam-Simon PhD, Ka Lok Chan MS, Huy Quach, Timothy A. Blauwkamp PhD, and David K. Hong MD.

Attendees will have the opportunity to connect with the Karius team by visiting booth #419. A comprehensive list of both oral abstracts and poster presentations is available on the Karius website at kariusdx.com/idweek.

About Karius, Inc.
Karius is a life sciences company focused on transforming infectious disease diagnosis with genomics through the innovative use of next-generation sequencing to analyze microbial cell-free DNA. The Karius laboratory is CLIA-certified and CAP-accredited to perform high-complexity clinical laboratory testing. The company’s genomics platform and clinically-curated pathogen database deliver insight into the microbial landscape, providing clinicians with a comprehensive, quantitative test capable of identifying more than a thousand pathogens directly from blood. For more information, visit kariusdx.com and follow us on Twitter at @kariusdx.

Read the full story at https://www.prweb.com/releases/karius_and_duke_demonstrate_that_the_karius_test_accurately_detects_and_quantifies_microbial_cell_free_dna_in_patients_with_infective_endocarditis/prweb15805667.htm.


'/>"/>
Source: PRWeb
Copyright©2018 Vocus, Inc.
All rights reserved


Related biology technology :

1. China: Innovative Hybrid PEEK-titanium Expandable Cage for DLIF and OLIF Procedures Demonstrated
2. Clinical Study Demonstrates that RPS Diagnostics FebriDx Rapid Point-of-Care Blood Test Can Accurately Distinguish Between Acute Bacterial and Viral Respiratory Infection
3. Brain Sentinel’s SPEAC® System Demonstrates Equivalence in Sensitivity to Detect Generalized Tonic Clonic Seizures to Video EEG
4. Global Surgeon Experience Demonstrates AxioMed Freedom® Viscoelastic Disc Will Be Revolutionary
5. Therapixs First-in-Class Therapy Demonstrates Reversal of Age-Related Cognitive Impairment in Pre-Clinical Study
6. Microscan To Demonstrate Advancements in Barcode and Machine Vision Technology at AACC Clinical Lab Expo 2017
7. Study of In-Situ Treatment Using Powder Activated Carbon Demonstrates Minimal Short- and Long-Term Effects on Benthic Communities
8. CNSDose to Demonstrate Leading Genetic Technology for Prescribing Antidepressants at the American Psychiatric Association Annual Meeting
9. Thermo Fisher Scientific Demonstrates Improved differentiation of Stem Cell-derived Neurons and Downstream Applications
10. PathSensors Demonstrates Breakthrough Mail Security Screening Solution at National Postal Forum 2017
11. BESI Full Scale Advanced Gasification Research Facility in University Park, Il Demonstrates Clean Waste Conversion for US Military
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/27/2018)... EWING, N.J. (PRWEB) , ... September 26, 2018 ... ... and DNA testing are way ahead of their primary care physicians, according to ... , For this study, patients and doctors were asked about consumer adoption of ...
(Date:9/27/2018)... ... September 27, 2018 , ... This past weekend ... SureAdhere Mobile Technology, Inc. announced they will formally merge companies and integrate their ... tuberculosis (TB) and other diseases. These two social enterprise corporations, both of which ...
(Date:9/22/2018)... (PRWEB) , ... September 20, ... ... are excited to announce a strategic venture. The synergistic combination of Predicine’s ... provides complimentary and comprehensive biomarker profiling to empower clinical trials in the ...
(Date:9/15/2018)... ... September 14, 2018 , ... Next-generation genomic sequencing is transforming ... new technologies, challenges remain. In the past, the sheer size of genomics data has ... is a new data ecosystem developed to advance cures by reducing the technological barriers ...
Breaking Biology Technology:
(Date:10/3/2018)... ... October 03, 2018 , ... Orbsen ... first-in-class stromal cell immunotherapies, announced that ORBCEL-M™, a second generation stromal cell ... progressive diabetic kidney disease in a four-site, pan-European Phase I/II clinical trial. ...
(Date:10/2/2018)... ... 2018 , ... Stuart is a fun-loving eight-year-old Labrador retriever. Like many labs, Stuart’s favorite ... loves playing ball so much that whenever anyone comes to our door, he grabs a ... fetch.” In early 2017, Stuart began limping and eventually could no longer play fetch. ...
(Date:10/2/2018)... ... October 02, 2018 , ... The ... 27th, 2018 at Tampa Convention Center. The Palo Alto-based face recognition company, Camvi ... on September 27th. Other speakers included U.S. Federal executives from Department of Defense ...
Breaking Biology News(10 mins):